Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients With Lymphoma
NCT06744075
·
clinicaltrials.gov ↗
NA
Phase
ACTIVE_NOT_RECRUITING
Status
108
Enrollment
OTHER
Sponsor class
Conditions
B-cell Lymphoma
Hodgkin Lymphoma
Interventions
OTHER:
Blood assessment
Sponsor
Centre Henri Becquerel